nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—PDE3A—coronary artery disease	0.606	1	CbGaD
Anagrelide—CYP1A2—Gemfibrozil—coronary artery disease	0.0519	0.437	CbGbCtD
Anagrelide—CYP1A2—Clopidogrel—coronary artery disease	0.045	0.378	CbGbCtD
Anagrelide—CYP1A2—Losartan—coronary artery disease	0.022	0.185	CbGbCtD
Anagrelide—Gastrointestinal pain—Perindopril—coronary artery disease	6.04e-05	0.000275	CcSEcCtD
Anagrelide—Pruritus—Olmesartan—coronary artery disease	6.03e-05	0.000275	CcSEcCtD
Anagrelide—Decreased appetite—Losartan—coronary artery disease	6.02e-05	0.000274	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	6.02e-05	0.000274	CcSEcCtD
Anagrelide—Abdominal pain—Captopril—coronary artery disease	6.01e-05	0.000274	CcSEcCtD
Anagrelide—Body temperature increased—Captopril—coronary artery disease	6.01e-05	0.000274	CcSEcCtD
Anagrelide—Dizziness—Simvastatin—coronary artery disease	6e-05	0.000273	CcSEcCtD
Anagrelide—Rash—Ezetimibe—coronary artery disease	6e-05	0.000273	CcSEcCtD
Anagrelide—Dermatitis—Ezetimibe—coronary artery disease	5.99e-05	0.000273	CcSEcCtD
Anagrelide—Confusional state—Ramipril—coronary artery disease	5.99e-05	0.000273	CcSEcCtD
Anagrelide—Discomfort—Timolol—coronary artery disease	5.99e-05	0.000273	CcSEcCtD
Anagrelide—Asthenia—Niacin—coronary artery disease	5.98e-05	0.000272	CcSEcCtD
Anagrelide—Fatigue—Losartan—coronary artery disease	5.97e-05	0.000272	CcSEcCtD
Anagrelide—Headache—Ezetimibe—coronary artery disease	5.96e-05	0.000271	CcSEcCtD
Anagrelide—Malaise—Lisinopril—coronary artery disease	5.95e-05	0.000271	CcSEcCtD
Anagrelide—Oedema—Ramipril—coronary artery disease	5.94e-05	0.000271	CcSEcCtD
Anagrelide—Dry mouth—Timolol—coronary artery disease	5.92e-05	0.00027	CcSEcCtD
Anagrelide—Pain—Losartan—coronary artery disease	5.92e-05	0.00027	CcSEcCtD
Anagrelide—Constipation—Losartan—coronary artery disease	5.92e-05	0.00027	CcSEcCtD
Anagrelide—Syncope—Lisinopril—coronary artery disease	5.92e-05	0.00027	CcSEcCtD
Anagrelide—Vomiting—Eplerenone—coronary artery disease	5.92e-05	0.00027	CcSEcCtD
Anagrelide—Feeling abnormal—Furosemide—coronary artery disease	5.92e-05	0.00027	CcSEcCtD
Anagrelide—Nausea—Fenofibrate—coronary artery disease	5.9e-05	0.000269	CcSEcCtD
Anagrelide—Pruritus—Niacin—coronary artery disease	5.89e-05	0.000268	CcSEcCtD
Anagrelide—Asthenia—Pravastatin—coronary artery disease	5.88e-05	0.000268	CcSEcCtD
Anagrelide—Gastrointestinal pain—Furosemide—coronary artery disease	5.87e-05	0.000268	CcSEcCtD
Anagrelide—Rash—Eplerenone—coronary artery disease	5.87e-05	0.000267	CcSEcCtD
Anagrelide—Urticaria—Perindopril—coronary artery disease	5.87e-05	0.000267	CcSEcCtD
Anagrelide—Dermatitis—Eplerenone—coronary artery disease	5.86e-05	0.000267	CcSEcCtD
Anagrelide—Diarrhoea—Valsartan—coronary artery disease	5.86e-05	0.000267	CcSEcCtD
Anagrelide—Confusional state—Timolol—coronary artery disease	5.86e-05	0.000267	CcSEcCtD
Anagrelide—Shock—Ramipril—coronary artery disease	5.84e-05	0.000266	CcSEcCtD
Anagrelide—Body temperature increased—Perindopril—coronary artery disease	5.84e-05	0.000266	CcSEcCtD
Anagrelide—Abdominal pain—Perindopril—coronary artery disease	5.84e-05	0.000266	CcSEcCtD
Anagrelide—Palpitations—Lisinopril—coronary artery disease	5.83e-05	0.000266	CcSEcCtD
Anagrelide—Diarrhoea—Olmesartan—coronary artery disease	5.83e-05	0.000266	CcSEcCtD
Anagrelide—Headache—Eplerenone—coronary artery disease	5.83e-05	0.000266	CcSEcCtD
Anagrelide—Nervous system disorder—Ramipril—coronary artery disease	5.83e-05	0.000265	CcSEcCtD
Anagrelide—Thrombocytopenia—Ramipril—coronary artery disease	5.82e-05	0.000265	CcSEcCtD
Anagrelide—Oedema—Timolol—coronary artery disease	5.81e-05	0.000265	CcSEcCtD
Anagrelide—Pruritus—Pravastatin—coronary artery disease	5.8e-05	0.000264	CcSEcCtD
Anagrelide—Loss of consciousness—Lisinopril—coronary artery disease	5.8e-05	0.000264	CcSEcCtD
Anagrelide—Nausea—Clopidogrel—coronary artery disease	5.8e-05	0.000264	CcSEcCtD
Anagrelide—Tachycardia—Ramipril—coronary artery disease	5.8e-05	0.000264	CcSEcCtD
Anagrelide—Skin disorder—Ramipril—coronary artery disease	5.77e-05	0.000263	CcSEcCtD
Anagrelide—Infection—Timolol—coronary artery disease	5.77e-05	0.000263	CcSEcCtD
Anagrelide—Vomiting—Simvastatin—coronary artery disease	5.77e-05	0.000263	CcSEcCtD
Anagrelide—Cough—Lisinopril—coronary artery disease	5.76e-05	0.000262	CcSEcCtD
Anagrelide—Nausea—Lovastatin—coronary artery disease	5.76e-05	0.000262	CcSEcCtD
Anagrelide—Hyperhidrosis—Ramipril—coronary artery disease	5.74e-05	0.000262	CcSEcCtD
Anagrelide—Rash—Simvastatin—coronary artery disease	5.72e-05	0.000261	CcSEcCtD
Anagrelide—Dermatitis—Simvastatin—coronary artery disease	5.71e-05	0.00026	CcSEcCtD
Anagrelide—Asthenia—Trandolapril—coronary artery disease	5.71e-05	0.00026	CcSEcCtD
Anagrelide—Shock—Timolol—coronary artery disease	5.71e-05	0.00026	CcSEcCtD
Anagrelide—Feeling abnormal—Losartan—coronary artery disease	5.71e-05	0.00026	CcSEcCtD
Anagrelide—Urticaria—Furosemide—coronary artery disease	5.7e-05	0.00026	CcSEcCtD
Anagrelide—Diarrhoea—Niacin—coronary artery disease	5.7e-05	0.00026	CcSEcCtD
Anagrelide—Nervous system disorder—Timolol—coronary artery disease	5.69e-05	0.000259	CcSEcCtD
Anagrelide—Asthenia—Enalapril—coronary artery disease	5.69e-05	0.000259	CcSEcCtD
Anagrelide—Headache—Simvastatin—coronary artery disease	5.68e-05	0.000259	CcSEcCtD
Anagrelide—Abdominal pain—Furosemide—coronary artery disease	5.68e-05	0.000259	CcSEcCtD
Anagrelide—Body temperature increased—Furosemide—coronary artery disease	5.68e-05	0.000259	CcSEcCtD
Anagrelide—Gastrointestinal pain—Losartan—coronary artery disease	5.66e-05	0.000258	CcSEcCtD
Anagrelide—Dizziness—Valsartan—coronary artery disease	5.66e-05	0.000258	CcSEcCtD
Anagrelide—Anorexia—Ramipril—coronary artery disease	5.66e-05	0.000258	CcSEcCtD
Anagrelide—Nausea—Ezetimibe—coronary artery disease	5.65e-05	0.000257	CcSEcCtD
Anagrelide—Skin disorder—Timolol—coronary artery disease	5.64e-05	0.000257	CcSEcCtD
Anagrelide—Dizziness—Olmesartan—coronary artery disease	5.64e-05	0.000257	CcSEcCtD
Anagrelide—Pruritus—Trandolapril—coronary artery disease	5.63e-05	0.000257	CcSEcCtD
Anagrelide—Arthralgia—Lisinopril—coronary artery disease	5.62e-05	0.000256	CcSEcCtD
Anagrelide—Myalgia—Lisinopril—coronary artery disease	5.62e-05	0.000256	CcSEcCtD
Anagrelide—Chest pain—Lisinopril—coronary artery disease	5.62e-05	0.000256	CcSEcCtD
Anagrelide—Hyperhidrosis—Timolol—coronary artery disease	5.61e-05	0.000256	CcSEcCtD
Anagrelide—Asthenia—Telmisartan—coronary artery disease	5.61e-05	0.000256	CcSEcCtD
Anagrelide—Pruritus—Enalapril—coronary artery disease	5.61e-05	0.000256	CcSEcCtD
Anagrelide—Diarrhoea—Pravastatin—coronary artery disease	5.61e-05	0.000256	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	5.58e-05	0.000254	CcSEcCtD
Anagrelide—Discomfort—Lisinopril—coronary artery disease	5.55e-05	0.000253	CcSEcCtD
Anagrelide—Hypotension—Ramipril—coronary artery disease	5.55e-05	0.000253	CcSEcCtD
Anagrelide—Anorexia—Timolol—coronary artery disease	5.54e-05	0.000252	CcSEcCtD
Anagrelide—Pruritus—Telmisartan—coronary artery disease	5.53e-05	0.000252	CcSEcCtD
Anagrelide—Nausea—Eplerenone—coronary artery disease	5.53e-05	0.000252	CcSEcCtD
Anagrelide—Dizziness—Niacin—coronary artery disease	5.51e-05	0.000251	CcSEcCtD
Anagrelide—Urticaria—Losartan—coronary artery disease	5.5e-05	0.000251	CcSEcCtD
Anagrelide—Dry mouth—Lisinopril—coronary artery disease	5.5e-05	0.00025	CcSEcCtD
Anagrelide—Body temperature increased—Losartan—coronary artery disease	5.48e-05	0.00025	CcSEcCtD
Anagrelide—Abdominal pain—Losartan—coronary artery disease	5.48e-05	0.00025	CcSEcCtD
Anagrelide—Asthenia—Captopril—coronary artery disease	5.46e-05	0.000249	CcSEcCtD
Anagrelide—Diarrhoea—Trandolapril—coronary artery disease	5.45e-05	0.000248	CcSEcCtD
Anagrelide—Vomiting—Valsartan—coronary artery disease	5.45e-05	0.000248	CcSEcCtD
Anagrelide—Confusional state—Lisinopril—coronary artery disease	5.43e-05	0.000248	CcSEcCtD
Anagrelide—Diarrhoea—Enalapril—coronary artery disease	5.43e-05	0.000247	CcSEcCtD
Anagrelide—Hypotension—Timolol—coronary artery disease	5.43e-05	0.000247	CcSEcCtD
Anagrelide—Dizziness—Pravastatin—coronary artery disease	5.42e-05	0.000247	CcSEcCtD
Anagrelide—Vomiting—Olmesartan—coronary artery disease	5.42e-05	0.000247	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Ramipril—coronary artery disease	5.41e-05	0.000247	CcSEcCtD
Anagrelide—Rash—Valsartan—coronary artery disease	5.4e-05	0.000246	CcSEcCtD
Anagrelide—Dermatitis—Valsartan—coronary artery disease	5.4e-05	0.000246	CcSEcCtD
Anagrelide—Nausea—Simvastatin—coronary artery disease	5.39e-05	0.000245	CcSEcCtD
Anagrelide—Oedema—Lisinopril—coronary artery disease	5.39e-05	0.000245	CcSEcCtD
Anagrelide—Pruritus—Captopril—coronary artery disease	5.38e-05	0.000245	CcSEcCtD
Anagrelide—Rash—Olmesartan—coronary artery disease	5.37e-05	0.000245	CcSEcCtD
Anagrelide—Insomnia—Ramipril—coronary artery disease	5.37e-05	0.000245	CcSEcCtD
Anagrelide—Dermatitis—Olmesartan—coronary artery disease	5.37e-05	0.000245	CcSEcCtD
Anagrelide—Headache—Valsartan—coronary artery disease	5.37e-05	0.000245	CcSEcCtD
Anagrelide—Diarrhoea—Telmisartan—coronary artery disease	5.35e-05	0.000244	CcSEcCtD
Anagrelide—Infection—Lisinopril—coronary artery disease	5.35e-05	0.000244	CcSEcCtD
Anagrelide—Headache—Olmesartan—coronary artery disease	5.34e-05	0.000243	CcSEcCtD
Anagrelide—Paraesthesia—Ramipril—coronary artery disease	5.33e-05	0.000243	CcSEcCtD
Anagrelide—Shock—Lisinopril—coronary artery disease	5.3e-05	0.000242	CcSEcCtD
Anagrelide—Asthenia—Perindopril—coronary artery disease	5.3e-05	0.000241	CcSEcCtD
Anagrelide—Dyspnoea—Ramipril—coronary artery disease	5.3e-05	0.000241	CcSEcCtD
Anagrelide—Vomiting—Niacin—coronary artery disease	5.3e-05	0.000241	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Timolol—coronary artery disease	5.29e-05	0.000241	CcSEcCtD
Anagrelide—Somnolence—Ramipril—coronary artery disease	5.28e-05	0.000241	CcSEcCtD
Anagrelide—Thrombocytopenia—Lisinopril—coronary artery disease	5.27e-05	0.00024	CcSEcCtD
Anagrelide—Dizziness—Trandolapril—coronary artery disease	5.27e-05	0.00024	CcSEcCtD
Anagrelide—Tachycardia—Lisinopril—coronary artery disease	5.26e-05	0.00024	CcSEcCtD
Anagrelide—Insomnia—Timolol—coronary artery disease	5.25e-05	0.000239	CcSEcCtD
Anagrelide—Rash—Niacin—coronary artery disease	5.25e-05	0.000239	CcSEcCtD
Anagrelide—Dermatitis—Niacin—coronary artery disease	5.25e-05	0.000239	CcSEcCtD
Anagrelide—Dizziness—Enalapril—coronary artery disease	5.24e-05	0.000239	CcSEcCtD
Anagrelide—Skin disorder—Lisinopril—coronary artery disease	5.23e-05	0.000238	CcSEcCtD
Anagrelide—Dyspepsia—Ramipril—coronary artery disease	5.23e-05	0.000238	CcSEcCtD
Anagrelide—Pruritus—Perindopril—coronary artery disease	5.23e-05	0.000238	CcSEcCtD
Anagrelide—Headache—Niacin—coronary artery disease	5.22e-05	0.000238	CcSEcCtD
Anagrelide—Paraesthesia—Timolol—coronary artery disease	5.21e-05	0.000238	CcSEcCtD
Anagrelide—Vomiting—Pravastatin—coronary artery disease	5.21e-05	0.000238	CcSEcCtD
Anagrelide—Hyperhidrosis—Lisinopril—coronary artery disease	5.21e-05	0.000237	CcSEcCtD
Anagrelide—Diarrhoea—Captopril—coronary artery disease	5.2e-05	0.000237	CcSEcCtD
Anagrelide—Dyspnoea—Timolol—coronary artery disease	5.18e-05	0.000236	CcSEcCtD
Anagrelide—Dizziness—Telmisartan—coronary artery disease	5.17e-05	0.000236	CcSEcCtD
Anagrelide—Rash—Pravastatin—coronary artery disease	5.17e-05	0.000236	CcSEcCtD
Anagrelide—Dermatitis—Pravastatin—coronary artery disease	5.17e-05	0.000235	CcSEcCtD
Anagrelide—Decreased appetite—Ramipril—coronary artery disease	5.16e-05	0.000235	CcSEcCtD
Anagrelide—Somnolence—Timolol—coronary artery disease	5.16e-05	0.000235	CcSEcCtD
Anagrelide—Asthenia—Furosemide—coronary artery disease	5.15e-05	0.000235	CcSEcCtD
Anagrelide—Headache—Pravastatin—coronary artery disease	5.14e-05	0.000234	CcSEcCtD
Anagrelide—Anorexia—Lisinopril—coronary artery disease	5.14e-05	0.000234	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Ramipril—coronary artery disease	5.13e-05	0.000234	CcSEcCtD
Anagrelide—Fatigue—Ramipril—coronary artery disease	5.12e-05	0.000233	CcSEcCtD
Anagrelide—Dyspepsia—Timolol—coronary artery disease	5.11e-05	0.000233	CcSEcCtD
Anagrelide—Nausea—Valsartan—coronary artery disease	5.09e-05	0.000232	CcSEcCtD
Anagrelide—Pruritus—Furosemide—coronary artery disease	5.08e-05	0.000231	CcSEcCtD
Anagrelide—Constipation—Ramipril—coronary artery disease	5.08e-05	0.000231	CcSEcCtD
Anagrelide—Nausea—Olmesartan—coronary artery disease	5.06e-05	0.000231	CcSEcCtD
Anagrelide—Vomiting—Trandolapril—coronary artery disease	5.06e-05	0.000231	CcSEcCtD
Anagrelide—Diarrhoea—Perindopril—coronary artery disease	5.05e-05	0.00023	CcSEcCtD
Anagrelide—Decreased appetite—Timolol—coronary artery disease	5.05e-05	0.00023	CcSEcCtD
Anagrelide—Vomiting—Enalapril—coronary artery disease	5.04e-05	0.00023	CcSEcCtD
Anagrelide—Hypotension—Lisinopril—coronary artery disease	5.03e-05	0.000229	CcSEcCtD
Anagrelide—Dizziness—Captopril—coronary artery disease	5.03e-05	0.000229	CcSEcCtD
Anagrelide—Rash—Trandolapril—coronary artery disease	5.02e-05	0.000229	CcSEcCtD
Anagrelide—Dermatitis—Trandolapril—coronary artery disease	5.02e-05	0.000229	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Timolol—coronary artery disease	5.01e-05	0.000228	CcSEcCtD
Anagrelide—Fatigue—Timolol—coronary artery disease	5.01e-05	0.000228	CcSEcCtD
Anagrelide—Rash—Enalapril—coronary artery disease	5e-05	0.000228	CcSEcCtD
Anagrelide—Dermatitis—Enalapril—coronary artery disease	5e-05	0.000228	CcSEcCtD
Anagrelide—Headache—Trandolapril—coronary artery disease	4.99e-05	0.000227	CcSEcCtD
Anagrelide—Vomiting—Telmisartan—coronary artery disease	4.97e-05	0.000227	CcSEcCtD
Anagrelide—Asthenia—Losartan—coronary artery disease	4.97e-05	0.000226	CcSEcCtD
Anagrelide—Headache—Enalapril—coronary artery disease	4.97e-05	0.000226	CcSEcCtD
Anagrelide—Pain—Timolol—coronary artery disease	4.97e-05	0.000226	CcSEcCtD
Anagrelide—Nausea—Niacin—coronary artery disease	4.95e-05	0.000225	CcSEcCtD
Anagrelide—Rash—Telmisartan—coronary artery disease	4.93e-05	0.000225	CcSEcCtD
Anagrelide—Dermatitis—Telmisartan—coronary artery disease	4.93e-05	0.000225	CcSEcCtD
Anagrelide—Diarrhoea—Furosemide—coronary artery disease	4.91e-05	0.000224	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Lisinopril—coronary artery disease	4.91e-05	0.000224	CcSEcCtD
Anagrelide—Pruritus—Losartan—coronary artery disease	4.9e-05	0.000223	CcSEcCtD
Anagrelide—Headache—Telmisartan—coronary artery disease	4.9e-05	0.000223	CcSEcCtD
Anagrelide—Feeling abnormal—Ramipril—coronary artery disease	4.9e-05	0.000223	CcSEcCtD
Anagrelide—Dizziness—Perindopril—coronary artery disease	4.88e-05	0.000223	CcSEcCtD
Anagrelide—Insomnia—Lisinopril—coronary artery disease	4.87e-05	0.000222	CcSEcCtD
Anagrelide—Nausea—Pravastatin—coronary artery disease	4.87e-05	0.000222	CcSEcCtD
Anagrelide—Gastrointestinal pain—Ramipril—coronary artery disease	4.86e-05	0.000221	CcSEcCtD
Anagrelide—Paraesthesia—Lisinopril—coronary artery disease	4.84e-05	0.00022	CcSEcCtD
Anagrelide—Vomiting—Captopril—coronary artery disease	4.84e-05	0.00022	CcSEcCtD
Anagrelide—Dyspnoea—Lisinopril—coronary artery disease	4.8e-05	0.000219	CcSEcCtD
Anagrelide—Rash—Captopril—coronary artery disease	4.8e-05	0.000219	CcSEcCtD
Anagrelide—Dermatitis—Captopril—coronary artery disease	4.79e-05	0.000218	CcSEcCtD
Anagrelide—Somnolence—Lisinopril—coronary artery disease	4.79e-05	0.000218	CcSEcCtD
Anagrelide—Feeling abnormal—Timolol—coronary artery disease	4.79e-05	0.000218	CcSEcCtD
Anagrelide—Headache—Captopril—coronary artery disease	4.77e-05	0.000217	CcSEcCtD
Anagrelide—Gastrointestinal pain—Timolol—coronary artery disease	4.75e-05	0.000216	CcSEcCtD
Anagrelide—Dizziness—Furosemide—coronary artery disease	4.75e-05	0.000216	CcSEcCtD
Anagrelide—Dyspepsia—Lisinopril—coronary artery disease	4.74e-05	0.000216	CcSEcCtD
Anagrelide—Diarrhoea—Losartan—coronary artery disease	4.74e-05	0.000216	CcSEcCtD
Anagrelide—Nausea—Trandolapril—coronary artery disease	4.73e-05	0.000216	CcSEcCtD
Anagrelide—Urticaria—Ramipril—coronary artery disease	4.72e-05	0.000215	CcSEcCtD
Anagrelide—Nausea—Enalapril—coronary artery disease	4.71e-05	0.000215	CcSEcCtD
Anagrelide—Vomiting—Perindopril—coronary artery disease	4.7e-05	0.000214	CcSEcCtD
Anagrelide—Abdominal pain—Ramipril—coronary artery disease	4.7e-05	0.000214	CcSEcCtD
Anagrelide—Body temperature increased—Ramipril—coronary artery disease	4.7e-05	0.000214	CcSEcCtD
Anagrelide—Decreased appetite—Lisinopril—coronary artery disease	4.68e-05	0.000213	CcSEcCtD
Anagrelide—Rash—Perindopril—coronary artery disease	4.66e-05	0.000212	CcSEcCtD
Anagrelide—Dermatitis—Perindopril—coronary artery disease	4.65e-05	0.000212	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Lisinopril—coronary artery disease	4.65e-05	0.000212	CcSEcCtD
Anagrelide—Nausea—Telmisartan—coronary artery disease	4.65e-05	0.000212	CcSEcCtD
Anagrelide—Fatigue—Lisinopril—coronary artery disease	4.64e-05	0.000212	CcSEcCtD
Anagrelide—Headache—Perindopril—coronary artery disease	4.63e-05	0.000211	CcSEcCtD
Anagrelide—Urticaria—Timolol—coronary artery disease	4.61e-05	0.00021	CcSEcCtD
Anagrelide—Pain—Lisinopril—coronary artery disease	4.61e-05	0.00021	CcSEcCtD
Anagrelide—Constipation—Lisinopril—coronary artery disease	4.61e-05	0.00021	CcSEcCtD
Anagrelide—Abdominal pain—Timolol—coronary artery disease	4.59e-05	0.000209	CcSEcCtD
Anagrelide—Body temperature increased—Timolol—coronary artery disease	4.59e-05	0.000209	CcSEcCtD
Anagrelide—Dizziness—Losartan—coronary artery disease	4.58e-05	0.000209	CcSEcCtD
Anagrelide—Vomiting—Furosemide—coronary artery disease	4.57e-05	0.000208	CcSEcCtD
Anagrelide—Rash—Furosemide—coronary artery disease	4.53e-05	0.000206	CcSEcCtD
Anagrelide—Dermatitis—Furosemide—coronary artery disease	4.52e-05	0.000206	CcSEcCtD
Anagrelide—Nausea—Captopril—coronary artery disease	4.52e-05	0.000206	CcSEcCtD
Anagrelide—Headache—Furosemide—coronary artery disease	4.5e-05	0.000205	CcSEcCtD
Anagrelide—Feeling abnormal—Lisinopril—coronary artery disease	4.44e-05	0.000202	CcSEcCtD
Anagrelide—Gastrointestinal pain—Lisinopril—coronary artery disease	4.41e-05	0.000201	CcSEcCtD
Anagrelide—Vomiting—Losartan—coronary artery disease	4.4e-05	0.000201	CcSEcCtD
Anagrelide—Nausea—Perindopril—coronary artery disease	4.39e-05	0.0002	CcSEcCtD
Anagrelide—Rash—Losartan—coronary artery disease	4.37e-05	0.000199	CcSEcCtD
Anagrelide—Dermatitis—Losartan—coronary artery disease	4.36e-05	0.000199	CcSEcCtD
Anagrelide—Headache—Losartan—coronary artery disease	4.34e-05	0.000198	CcSEcCtD
Anagrelide—Urticaria—Lisinopril—coronary artery disease	4.28e-05	0.000195	CcSEcCtD
Anagrelide—Nausea—Furosemide—coronary artery disease	4.26e-05	0.000194	CcSEcCtD
Anagrelide—Asthenia—Ramipril—coronary artery disease	4.26e-05	0.000194	CcSEcCtD
Anagrelide—Abdominal pain—Lisinopril—coronary artery disease	4.26e-05	0.000194	CcSEcCtD
Anagrelide—Body temperature increased—Lisinopril—coronary artery disease	4.26e-05	0.000194	CcSEcCtD
Anagrelide—Pruritus—Ramipril—coronary artery disease	4.2e-05	0.000191	CcSEcCtD
Anagrelide—Asthenia—Timolol—coronary artery disease	4.17e-05	0.00019	CcSEcCtD
Anagrelide—Nausea—Losartan—coronary artery disease	4.11e-05	0.000187	CcSEcCtD
Anagrelide—Pruritus—Timolol—coronary artery disease	4.11e-05	0.000187	CcSEcCtD
Anagrelide—Diarrhoea—Ramipril—coronary artery disease	4.06e-05	0.000185	CcSEcCtD
Anagrelide—Diarrhoea—Timolol—coronary artery disease	3.97e-05	0.000181	CcSEcCtD
Anagrelide—Dizziness—Ramipril—coronary artery disease	3.93e-05	0.000179	CcSEcCtD
Anagrelide—Asthenia—Lisinopril—coronary artery disease	3.87e-05	0.000176	CcSEcCtD
Anagrelide—Dizziness—Timolol—coronary artery disease	3.84e-05	0.000175	CcSEcCtD
Anagrelide—Pruritus—Lisinopril—coronary artery disease	3.81e-05	0.000174	CcSEcCtD
Anagrelide—Vomiting—Ramipril—coronary artery disease	3.78e-05	0.000172	CcSEcCtD
Anagrelide—Rash—Ramipril—coronary artery disease	3.75e-05	0.000171	CcSEcCtD
Anagrelide—Dermatitis—Ramipril—coronary artery disease	3.74e-05	0.000171	CcSEcCtD
Anagrelide—Headache—Ramipril—coronary artery disease	3.72e-05	0.00017	CcSEcCtD
Anagrelide—Vomiting—Timolol—coronary artery disease	3.69e-05	0.000168	CcSEcCtD
Anagrelide—Diarrhoea—Lisinopril—coronary artery disease	3.69e-05	0.000168	CcSEcCtD
Anagrelide—Rash—Timolol—coronary artery disease	3.66e-05	0.000167	CcSEcCtD
Anagrelide—Dermatitis—Timolol—coronary artery disease	3.66e-05	0.000167	CcSEcCtD
Anagrelide—Headache—Timolol—coronary artery disease	3.64e-05	0.000166	CcSEcCtD
Anagrelide—Dizziness—Lisinopril—coronary artery disease	3.56e-05	0.000162	CcSEcCtD
Anagrelide—Nausea—Ramipril—coronary artery disease	3.53e-05	0.000161	CcSEcCtD
Anagrelide—Nausea—Timolol—coronary artery disease	3.45e-05	0.000157	CcSEcCtD
Anagrelide—Vomiting—Lisinopril—coronary artery disease	3.43e-05	0.000156	CcSEcCtD
Anagrelide—Rash—Lisinopril—coronary artery disease	3.4e-05	0.000155	CcSEcCtD
Anagrelide—Dermatitis—Lisinopril—coronary artery disease	3.39e-05	0.000155	CcSEcCtD
Anagrelide—Headache—Lisinopril—coronary artery disease	3.37e-05	0.000154	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—PRKCD—coronary artery disease	3.26e-05	0.000585	CbGpPWpGaD
Anagrelide—Nausea—Lisinopril—coronary artery disease	3.2e-05	0.000146	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—FGB—coronary artery disease	3.19e-05	0.000574	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HTR2A—coronary artery disease	3.19e-05	0.000573	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—C3—coronary artery disease	3.18e-05	0.000572	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDNRB—coronary artery disease	3.16e-05	0.000568	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—coronary artery disease	3.15e-05	0.000566	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—THBS1—coronary artery disease	3.11e-05	0.000559	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSMB5—coronary artery disease	3.08e-05	0.000554	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSMA6—coronary artery disease	3.08e-05	0.000554	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—F2—coronary artery disease	3.08e-05	0.000553	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—coronary artery disease	3.07e-05	0.000551	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—coronary artery disease	3.03e-05	0.000544	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AGT—coronary artery disease	3.02e-05	0.000543	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SLC27A1—coronary artery disease	3.02e-05	0.000542	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDNRA—coronary artery disease	2.99e-05	0.000536	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CYBA—coronary artery disease	2.97e-05	0.000534	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRB1—coronary artery disease	2.97e-05	0.000534	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—coronary artery disease	2.96e-05	0.000532	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LCAT—coronary artery disease	2.96e-05	0.000532	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—DUSP6—coronary artery disease	2.96e-05	0.000532	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLAT—coronary artery disease	2.91e-05	0.000523	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA4—coronary artery disease	2.9e-05	0.000522	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CKMT1B—coronary artery disease	2.87e-05	0.000516	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL12—coronary artery disease	2.81e-05	0.000504	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BDKRB2—coronary artery disease	2.81e-05	0.000504	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—POMC—coronary artery disease	2.8e-05	0.000504	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—F2—coronary artery disease	2.79e-05	0.000502	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—coronary artery disease	2.79e-05	0.000501	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6ST—coronary artery disease	2.78e-05	0.0005	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JUNB—coronary artery disease	2.75e-05	0.000495	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLCB1—coronary artery disease	2.74e-05	0.000493	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11B2—coronary artery disease	2.72e-05	0.000488	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—TXNRD1—coronary artery disease	2.72e-05	0.000488	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR7—coronary artery disease	2.69e-05	0.000483	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ARNTL—coronary artery disease	2.64e-05	0.000474	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HADH—coronary artery disease	2.64e-05	0.000474	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ITGAV—coronary artery disease	2.56e-05	0.00046	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB1—coronary artery disease	2.56e-05	0.000459	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KNG1—coronary artery disease	2.55e-05	0.000459	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—POMC—coronary artery disease	2.54e-05	0.000457	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CREB1—coronary artery disease	2.54e-05	0.000457	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGTR1—coronary artery disease	2.54e-05	0.000456	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MAPK1—coronary artery disease	2.51e-05	0.000451	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G2A—coronary artery disease	2.5e-05	0.000449	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA2—coronary artery disease	2.5e-05	0.000449	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPX2—coronary artery disease	2.5e-05	0.000449	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCL2—coronary artery disease	2.49e-05	0.000447	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6R—coronary artery disease	2.48e-05	0.000446	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL10—coronary artery disease	2.48e-05	0.000446	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PLG—coronary artery disease	2.47e-05	0.000444	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—coronary artery disease	2.47e-05	0.000444	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCG5—coronary artery disease	2.47e-05	0.000444	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HADHA—coronary artery disease	2.44e-05	0.000438	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADRB2—coronary artery disease	2.41e-05	0.000433	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPA—coronary artery disease	2.39e-05	0.000429	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCE—coronary artery disease	2.38e-05	0.000427	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—JAK2—coronary artery disease	2.38e-05	0.000427	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SOCS1—coronary artery disease	2.37e-05	0.000426	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—S100B—coronary artery disease	2.37e-05	0.000425	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SOCS3—coronary artery disease	2.34e-05	0.000421	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CKM—coronary artery disease	2.34e-05	0.00042	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UQCRFS1—coronary artery disease	2.34e-05	0.00042	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPAP2B—coronary artery disease	2.34e-05	0.00042	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFBR2—coronary artery disease	2.31e-05	0.000416	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KITLG—coronary artery disease	2.31e-05	0.000416	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA5—coronary artery disease	2.29e-05	0.000411	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP3—coronary artery disease	2.26e-05	0.000406	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT5A—coronary artery disease	2.26e-05	0.000406	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—coronary artery disease	2.24e-05	0.000403	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G1B—coronary artery disease	2.2e-05	0.000396	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOB—coronary artery disease	2.19e-05	0.000393	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CA—coronary artery disease	2.18e-05	0.000391	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH6A1—coronary artery disease	2.18e-05	0.000391	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SULT4A1—coronary artery disease	2.18e-05	0.000391	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CKMT2—coronary artery disease	2.18e-05	0.000391	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PDK4—coronary artery disease	2.18e-05	0.000391	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PYGM—coronary artery disease	2.18e-05	0.000391	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—POMC—coronary artery disease	2.17e-05	0.00039	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL8—coronary artery disease	2.17e-05	0.000389	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—JAK2—coronary artery disease	2.16e-05	0.000388	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EDN1—coronary artery disease	2.15e-05	0.000387	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL5—coronary artery disease	2.14e-05	0.000384	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF1—coronary artery disease	2.1e-05	0.000378	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CSF2—coronary artery disease	2.1e-05	0.000378	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LPL—coronary artery disease	2.09e-05	0.000375	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RPS6KB1—coronary artery disease	2.07e-05	0.000372	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MEF2C—coronary artery disease	2.07e-05	0.000372	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ITGB3—coronary artery disease	2.02e-05	0.000362	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL8—coronary artery disease	1.97e-05	0.000354	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PPP2CA—coronary artery disease	1.96e-05	0.000352	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GYG1—coronary artery disease	1.94e-05	0.000348	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LDHA—coronary artery disease	1.94e-05	0.000348	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMGCS2—coronary artery disease	1.94e-05	0.000348	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GK—coronary artery disease	1.94e-05	0.000348	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GATM—coronary artery disease	1.94e-05	0.000348	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PFKM—coronary artery disease	1.94e-05	0.000348	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCD—coronary artery disease	1.92e-05	0.000346	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—coronary artery disease	1.9e-05	0.00034	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—coronary artery disease	1.9e-05	0.00034	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C19—coronary artery disease	1.9e-05	0.00034	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOC3—coronary artery disease	1.88e-05	0.000338	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR2A—coronary artery disease	1.88e-05	0.000338	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—C3—coronary artery disease	1.88e-05	0.000338	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LDLR—coronary artery disease	1.87e-05	0.000336	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCH1—coronary artery disease	1.85e-05	0.000332	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AK1—coronary artery disease	1.85e-05	0.000332	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CETP—coronary artery disease	1.83e-05	0.000328	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—SDC1—coronary artery disease	1.81e-05	0.000325	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HIF1A—coronary artery disease	1.79e-05	0.000322	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGT—coronary artery disease	1.79e-05	0.000321	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—coronary artery disease	1.78e-05	0.000319	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MDH2—coronary artery disease	1.77e-05	0.000319	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCD1—coronary artery disease	1.77e-05	0.000319	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UGCG—coronary artery disease	1.77e-05	0.000319	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPAT—coronary artery disease	1.77e-05	0.000319	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOE—coronary artery disease	1.75e-05	0.000314	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—coronary artery disease	1.75e-05	0.000314	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOA1—coronary artery disease	1.73e-05	0.000311	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—coronary artery disease	1.71e-05	0.000308	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PGM1—coronary artery disease	1.71e-05	0.000307	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK14—coronary artery disease	1.7e-05	0.000306	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ESR1—coronary artery disease	1.67e-05	0.0003	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—coronary artery disease	1.67e-05	0.0003	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—coronary artery disease	1.65e-05	0.000297	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FN1—coronary artery disease	1.65e-05	0.000297	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—F2—coronary artery disease	1.65e-05	0.000297	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PYGB—coronary artery disease	1.65e-05	0.000296	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CKB—coronary artery disease	1.65e-05	0.000296	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6ST—coronary artery disease	1.64e-05	0.000295	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NFKBIA—coronary artery disease	1.63e-05	0.000293	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KIT—coronary artery disease	1.58e-05	0.000284	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLIN1—coronary artery disease	1.55e-05	0.000278	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—DLAT—coronary artery disease	1.55e-05	0.000278	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—COX5B—coronary artery disease	1.55e-05	0.000278	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM2—coronary artery disease	1.55e-05	0.000278	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PFKFB3—coronary artery disease	1.55e-05	0.000278	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—GSK3B—coronary artery disease	1.52e-05	0.000272	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CREB1—coronary artery disease	1.5e-05	0.00027	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—POMC—coronary artery disease	1.5e-05	0.00027	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—coronary artery disease	1.47e-05	0.000265	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL2—coronary artery disease	1.47e-05	0.000264	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SULT1E1—coronary artery disease	1.47e-05	0.000264	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6R—coronary artery disease	1.47e-05	0.000263	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1—coronary artery disease	1.45e-05	0.00026	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—MAPK1—coronary artery disease	1.44e-05	0.000259	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—coronary artery disease	1.43e-05	0.000256	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKR1B1—coronary artery disease	1.4e-05	0.000252	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HK2—coronary artery disease	1.4e-05	0.000252	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CA—coronary artery disease	1.38e-05	0.000247	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—coronary artery disease	1.37e-05	0.000247	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC27A1—coronary artery disease	1.34e-05	0.000241	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF2—coronary artery disease	1.33e-05	0.000239	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LCAT—coronary artery disease	1.32e-05	0.000237	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CPT1B—coronary artery disease	1.32e-05	0.000237	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—coronary artery disease	1.31e-05	0.000236	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA4—coronary artery disease	1.29e-05	0.000232	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JAK2—coronary artery disease	1.27e-05	0.000229	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—coronary artery disease	1.27e-05	0.000228	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PDHA1—coronary artery disease	1.25e-05	0.000224	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCLM—coronary artery disease	1.25e-05	0.000224	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CA—coronary artery disease	1.25e-05	0.000224	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—coronary artery disease	1.21e-05	0.000218	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TXNRD1—coronary artery disease	1.21e-05	0.000217	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP11B2—coronary artery disease	1.21e-05	0.000217	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC22A3—coronary artery disease	1.19e-05	0.000214	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ARNTL—coronary artery disease	1.17e-05	0.000211	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HADH—coronary artery disease	1.17e-05	0.000211	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL8—coronary artery disease	1.16e-05	0.000209	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—coronary artery disease	1.16e-05	0.000208	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—coronary artery disease	1.13e-05	0.000203	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—coronary artery disease	1.12e-05	0.000202	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLA2G2A—coronary artery disease	1.11e-05	0.0002	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPX2—coronary artery disease	1.11e-05	0.0002	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA2—coronary artery disease	1.11e-05	0.0002	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—coronary artery disease	1.11e-05	0.0002	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—coronary artery disease	1.11e-05	0.000199	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPX4—coronary artery disease	1.1e-05	0.000198	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCG5—coronary artery disease	1.1e-05	0.000198	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SULT1A1—coronary artery disease	1.1e-05	0.000198	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HK1—coronary artery disease	1.1e-05	0.000198	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—coronary artery disease	1.1e-05	0.000197	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HADHA—coronary artery disease	1.09e-05	0.000195	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCND1—coronary artery disease	1.08e-05	0.000195	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA1—coronary artery disease	1.07e-05	0.000193	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPA—coronary artery disease	1.06e-05	0.000191	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—coronary artery disease	1.05e-05	0.000189	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCB3—coronary artery disease	1.03e-05	0.000185	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—coronary artery disease	1.02e-05	0.000183	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA5—coronary artery disease	1.02e-05	0.000183	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—P4HB—coronary artery disease	9.99e-06	0.000179	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—coronary artery disease	9.89e-06	0.000178	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLA2G1B—coronary artery disease	9.8e-06	0.000176	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—coronary artery disease	9.69e-06	0.000174	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—coronary artery disease	9.58e-06	0.000172	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—coronary artery disease	9.45e-06	0.00017	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—VCAN—coronary artery disease	9.24e-06	0.000166	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDOA—coronary artery disease	9.17e-06	0.000165	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—DCN—coronary artery disease	8.9e-06	0.00016	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—coronary artery disease	8.67e-06	0.000156	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH2—coronary artery disease	8.66e-06	0.000156	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK1—coronary artery disease	8.5e-06	0.000153	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	8.44e-06	0.000152	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LIPC—coronary artery disease	8.44e-06	0.000152	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HBA1—coronary artery disease	8.44e-06	0.000152	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3C2A—coronary artery disease	8.44e-06	0.000152	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2C19—coronary artery disease	8.44e-06	0.000152	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOC3—coronary artery disease	8.39e-06	0.000151	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LDLR—coronary artery disease	8.34e-06	0.00015	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	8.33e-06	0.00015	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC9A1—coronary artery disease	8.24e-06	0.000148	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—coronary artery disease	8.24e-06	0.000148	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCLC—coronary artery disease	8.14e-06	0.000146	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CETP—coronary artery disease	8.14e-06	0.000146	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SDC1—coronary artery disease	8.05e-06	0.000145	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PSMA6—coronary artery disease	7.61e-06	0.000137	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PSMB5—coronary artery disease	7.61e-06	0.000137	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	7.59e-06	0.000136	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CTGF—coronary artery disease	7.43e-06	0.000133	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CA—coronary artery disease	7.38e-06	0.000133	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GOT2—coronary artery disease	7.36e-06	0.000132	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMGCR—coronary artery disease	7.36e-06	0.000132	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCB1—coronary artery disease	6.77e-06	0.000122	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	6.64e-06	0.000119	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCA1—coronary artery disease	6.56e-06	0.000118	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—coronary artery disease	6.53e-06	0.000117	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GGT1—coronary artery disease	6.36e-06	0.000114	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GOT1—coronary artery disease	6.36e-06	0.000114	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—coronary artery disease	6.03e-06	0.000108	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTP1—coronary artery disease	5.71e-06	0.000103	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARGC1A—coronary artery disease	5.66e-06	0.000102	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—coronary artery disease	5.63e-06	0.000101	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAT—coronary artery disease	5.56e-06	9.98e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOB—coronary artery disease	5.39e-06	9.69e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—coronary artery disease	5.25e-06	9.43e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPL—coronary artery disease	5.15e-06	9.25e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPX1—coronary artery disease	5.02e-06	9.03e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CD36—coronary artery disease	4.89e-06	8.79e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPP2CA—coronary artery disease	4.83e-06	8.68e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—coronary artery disease	4.64e-06	8.33e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AGT—coronary artery disease	4.41e-06	7.92e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOE—coronary artery disease	4.32e-06	7.76e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA1—coronary artery disease	4.27e-06	7.67e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	4.09e-06	7.34e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARG—coronary artery disease	3.76e-06	6.76e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—POMC—coronary artery disease	3.71e-06	6.66e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—coronary artery disease	3.38e-06	6.07e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—coronary artery disease	3.23e-06	5.81e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—coronary artery disease	2.96e-06	5.31e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CA—coronary artery disease	1.82e-06	3.27e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—coronary artery disease	1.49e-06	2.67e-05	CbGpPWpGaD
